Novavax, Inc. (NVAX) News
Track canonical SquawkNews coverage tagged to NVAX, Novavax, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NVAX: Strategic shift to licensing and Matrix-M partnerships drives growth in vaccines and oncology
A major strategic pivot has shifted focus to licensing and partnerships, with Matrix-M technology now central to both infectious disease and oncology pipelines. Key alliances with top pharma, strong financial milestones,
EQUITY | Sep 09, 2026, 08:11 PM UTC
L
NVAX: Major pharma partnerships, Matrix-M expansion, and global commercialization drive future growth
The company shifted from a single-product focus to global technology licensing, securing major pharma partnerships and reducing costs. Matrix-M is used in infectious disease and oncology, with new data expected. Global c
EQUITY | Sep 09, 2026, 07:37 PM UTC
L
NVAX - Novavax to Participate in September Investor Conferences
NVAX - Novavax to Participate in September Investor Conferences
EQUITY | Sep 02, 2026, 09:00 PM UTC
L
Novavax management to participate in September investor conferences
Novavax said management will participate in upcoming September investor conferences. Live webcasts of the fireside chats will be available on the company’s “Events & Presentations” page.
EQUITY | Sep 02, 2026, 09:00 PM UTC
L
Novavax shares rise after FDA authorization and guidance upgrade
Novavax shares are trading higher Tuesday after U.S. FDA emergency use authorization for its updated 2026-2027 Nuvaxovid vaccine and an earlier Q2 update that raised full-year revenue guidance.
EARNINGS | Sep 01, 2026, 04:47 PM UTC
L
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
EQUITY | Aug 28, 2026, 10:35 PM UTC
L
NVAX - Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vac
NVAX - Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
EQUITY | Aug 28, 2026, 12:30 PM UTC
M
US FDA approves updated COVID vaccines for 2026-27 season
US FDA approves updated COVID vaccines for the 2026-27 season.
REGULATION | Aug 27, 2026, 09:41 PM UTC
L
Novavax shares rise after Q2 revenue beat, 2026 guidance lift
Novavax says Q2 revenue of $56.7 million topped Wall Street consensus and it raised full-year 2026 revenue guidance to $235 million-$275 million, supporting a late-morning stock gain.
EARNINGS | Aug 25, 2026, 03:31 PM UTC
H
Novavax rises as biotech rally spreads after Merck-Moderna data
Novavax shares are trading higher Wednesday as a broad biotech rally follows Merck and Moderna Phase 3 INTerpath-001 melanoma results; no Novavax-specific catalyst was supplied.
EQUITY | Aug 19, 2026, 04:33 PM UTC
H
US President Signs Order On Childhood Vaccines
US President signs executive order on childhood vaccines
REGULATION | Aug 10, 2026, 05:50 PM UTC
L
Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est
Novavax (NASDAQ: NVAX ) raises FY2026 sales outlook from $230.000 million-$270.000 million to $235.000 million-$275.000 million vs $389.234 million estimate.
EARNINGS | Aug 06, 2026, 12:02 PM UTC
L
NVAX NVAX - Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
NVAX NVAX - Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
EARNINGS | Aug 06, 2026, 12:00 PM UTC
L
NVAX NVAX - Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
NVAX NVAX - Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
EARNINGS | Jul 30, 2026, 11:00 AM UTC
H
Novavax put volume heavy and directionally bearish
Bearish flow noted in Novavax with 2,130 puts trading, or 4x expected. Most active are Jul-26 8 puts and 7/31 weekly 8 puts, with total volume in those strikes near 1,500 contracts. The Put/Call Ratio is 2.14, while ATM
EQUITY | Jul 10, 2026, 03:15 PM UTC